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Efficacy and safety of intravenous iron therapy as an
alternative/adjunct to allogeneic blood transfusion
Abstract
Anaemia is a common condition among patients admitted to hospital medicosurgical departments, as
well as in critically ill patients. Anaemia is more frequently due to absolute iron deficiency (e.g. chronic
blood loss) or functional iron deficiency (e.g. chronic inflammatory states), with other causes being less
frequent. In addition, preoperative anaemia is one of the major predictive factors for perioperative blood
transfusion. In surgical patients, postoperative anaemia is mainly caused by perioperative blood loss,
and it might be aggravated by inflammation-induced inhibition of erythropoietin and functional iron
deficiency (a condition that cannot be corrected by the administration of oral iron). All these
mechanisms may be involved in the anaemia of the critically ill. Intravenous iron administration seems
to be safe, as very few severe side-effects were observed, and may result in hastened recovery from
anaemia and lower transfusion requirements. However, it is noteworthy that many of the
recommendations given for intravenous iron treatment are not supported by a high level of evidence and
this must be borne in mind when making decisions regarding its application to a particular patient.
Nonetheless, this also indicates the need for further large, randomized controlled trials on the safety and
efficacy of intravenous iron for the treatment of anaemia in different clinical settings.
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Abstract 
Anaemia is common in medical, surgical  and critically ill patients, mostly due to absolute or functional 
iron deficiency (e.g.chronic blood loss or chronic inflammatory states respectively). Other causes are 
less frequent. Its presence is predictive for perioperative blood transfusion. Postoperative anaemia is 
mainly caused by blood loss, and may be aggravated by inflammation-induced inhibition of 
erythropoietin and functional iron deficiency (not correctable by the administration of oral iron). All 
these mechanisms may be involved in the anaemia of the critically ill. Intravenous iron administration 
seems to be safe, with few severe side-effects, and may hasten recovery from anaemia and reduce 
transfusion requirements. All the same, many indications given for IV iron are not supported by much 
evidence, which must be borne in mind when making decisions for a particular patient. Thus we need 
large, randomized controlled trials on the safety and efficacy of IV iron for the treatment of anaemia in 
various clinical settings. 
 
1. INTRODUCTION 
Iron metabolism is tightly regulated. The enterocyte absorbs haem-iron and inorganic iron via the 
apical membrane and releases it to the blood through its baso-lateral membrane by means of 
ferroportin [1]. Iron storage in the liver and macrophages is mostly in the form of ferritin. Transferrin 
effects iron transport from absorption and storage sites to the bone marrow, and makes iron available 
for incorporation into haemoglobin (Hb) (Figure 1) [1]. 
Under physiological conditions, there is a balance between iron absorption, transport, and storage in 
the human body. But iron deficiency (ID) and iron deficiency anaemia (IDA) are common in medical, 
surgical, and critically ill patients, and result from the interplay of three distinct risk factors: increased 
iron requirements, limited external supply, and blood loss (Table 1) [2]. Iron deficiency can be either 
absolute or functional. In absolute ID, the iron stores are depleted; in functional iron deficiency (FID), 
iron stores, although replete, cannot be mobilized as fast as necessary from the macrophages of the 
reticulo-endothelial system (RES) to the bone marrow. FID occurs in the anaemia of inflammatory 
diseases because iron is trapped in the RES as a result of increased secretion of hepcidin, a hormone 
that controls ferroportin activity in releasing iron from cells (Figure 1) [1,2]. FID may also occur in 
therapy with erythropoiesis-stimulating agents (ESAs), such as epoetin or darbopoetin, which place a 
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significant demand on iron stores that may surpass the iron-release capacity of the RES [3]. Thus, 
laboratory tests for ID fall into two categories: measurements of body iron depletion, and those 
reflecting iron-deficient red cell production (Table 2) [4].The appropriate combination of these tests will 
help to establish a correct diagnosis of anaemia and iron deficiency status [5]. 
Allogeneic blood transfusion (ABT) rapidly and effectively restores the haemoglobin (Hb) levels. This 
may avert the deleterious effects of severe anaemia, especially when acute or in elderly patients with 
impaired cardio-respiratory compensatory mechanisms. But ABT, though safer than it was, is not risk-
free. It reflects the current state of health of society, and new illnesses and infections influence blood 
safety unpredictably [6]. Thus, concerns for the reduction of ABT-related risks have prompted the 
review of transfusion practices, and the search for a safer and more biologically rational treatment of 
anaemia (i.e., pharmacological treatment). This should also hasten recovery of a patent’s functional 
capacity.  
In IDA (resulting from inadequate intake, chronic blood loss, etc), iron absorption is increased and, 
provided there is no pathology of the gastrointestinal tract, oral iron administration is usually effective 
to correct anaemia.. By contrast, anaemia can occur in chronic inflammation (e.g., rheumatoid arthritis, 
Crohn’s disease, chronic renal or heart failure, or cancer), and in acute processes (e.g., trauma or 
surgery) associated with ID. In those cases the utility of oral iron may be limited, since absorption is 
down-regulated, and the small amount of iron absorbed is sequestered in the RES. Hepcidin  an 
hepatic acute-phase protein, plays a major role in both processes through its effects on ferroportin 
expression and activity (Figure 1) [1,5]. Intravenous (IV) iron may be a more effective mode of 
administration in these situations, as well as in cases of intolerance or contraindication to oral iron, 
treatment with ESAs, imminent surgery, or severe anaemia. In this review we will focus on the efficacy 
and safety of intravenous iron administration as an alternative or adjunct to ABT for the treatment of 
anaemic patients in different clinical contexts. 
2. INTRAVENOUS IRON AGENTS 
2.1 Structure, biochemistry, and pharmacokinetic properties 
All IV iron agents are colloids with spheroidal iron-carbohydrate nanoparticles. Each particle consists 
of an iron-oxyhydroxide core (Fe [III]) and a carbohydrate shell that stabilizes the iron-oxyhydroxide 
core. Three different products are used in clinical practice: iron dextran (73 – 265 kDa), iron gluconate 
(38 kDa), and iron sucrose (43 kDa) [9,10], and differences in core size and carbohydrate chemistry 
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determine pharmacological and biological differences between the different agents. This includes 
clearance after injection, iron release in vitro, early evidence of iron bioactivity in vivo, and maximum 
tolerated dose and rate of infusion [7,8] (Table 3). 
After IV injection, iron-carbohydrate agents mix with plasma, then enter the RES directly from the 
intravascular fluid compartment. Resident phagocytes of the liver, spleen, and bone marrow remove 
iron agent from the circulating plasma. Within phagocytes, iron is released from the iron-carbohydrate 
compound into a low molecular weight iron pool. Low molecular weight iron is either incorporated by 
ferritin into intracellular iron stores, or leaves the cell to bind with the extracellular iron-binding protein 
transferrin [11]. A small fraction, however, likely bypasses the intracellular steps and donates iron 
directly to transferrin in plasma (Table 3) [8]. Transferrin binds to receptors on the surface of erythroid 
precursors, and the resulting internalization of the iron-transferrin-receptor complex supplies iron for 
Hb synthesis and maturation of the red cell [11]. 
The precise cellular events by which RES phagocytes take up carbohydrate compounds and thereby 
clear them from plasma are not clear, although it seems to be a saturable process and to depend on 
molecular weight [11]. In contrast, the rate of transfer of iron from RES into circulating red cells seems 
to depend on the severity of ID, the rate of erythropoiesis, or circulating factors that influence those 
disorders (e.g., hepcidin). It is more rapid and more complete with ID than with cancer or inflammation 
[11]. In addition, given the same iron loading dose, experimental animals show higher RES iron levels 
after iron dextran than after ferric gluconate and iron sucrose, suggesting that the rate of metabolism 
and utilization of IV iron may be lower for agents with higher molecular weights [11]. 
2.2 Adverse side effects. 
A. Allergic and anaphylactic reactions. The stability of the dextran complex allows administration of 
high single doses (‘‘total dose therapy’’). However, these iron complexes may cause dextran-induced 
anaphylactic reactions in some patients receiving iron dextran [12]. In contrast, iron gluconate is labile, 
with fast degradation kinetics, and can cause acute adverse reactions related to labile iron release. 
Non-transferrin-bound labile iron may induce acute endothelial cell injury and a transient capillary leak 
syndrome (nausea, hypotension, tachycardia, chest pain, dyspnoea due to lung oedema, and oedema 
of the hands and feet) that should not be misread as anaphylaxis [7]. To avoid these side effects, the 
maximum recommended single dose is 125 mg and the administration of total dose is not 
recommended. Finally, with iron sucrose, if the infusion is too fast (above 4 mg Fe3+/min) or the single 
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total iron dose too high (above 7 mg Fe3+/kg), labile iron toxicity might occur [7]. Single doses of up to 
300 mg are safe, and the maximal recommended dosage is 600 mg/week [12]. Overall, iron sucrose is 
currently considered the safest IV iron preparation [9,10]. 
Although no serious life-threatening adverse events have been reported in the studies reviewed in this 
paper, the numbers of patients included are not large enough to draw conclusions about the safety of 
IV iron agents in different clinical settings. Therefore, this section will focus on adverse drug events 
(ADEs) associated with parenteral iron in chronic kidney disease (CKD) patients. 
The United States Food and Drug Administration (FDA) reported adjusted-rate adverse drug events 
(ADEs) per 100 mg dose of four formulations of intravenous iron during 2001–2003. These included 
higher and lower molecular weight iron dextran, sodium ferric gluconate complex, and iron sucrose. In 
these data, the total parenteral iron-related ADEs were 1141 amongst approximately 30 million doses 
given (about 38 ADEs per million), with 11 deaths (7 iron dextran, 3 iron gluconate, 1 iron sucrose) 
[13]. Relative to lower molecular weight iron dextran, total and life-threatening ADEs were significantly 
more frequent among recipients of higher molecular weight iron dextran and less so with sodium ferric 
gluconate complex and iron sucrose. The absolute rates of life-threatening ADEs were 0.6, 0.9, 3.3 
and 11.3 per 106 doses for iron sucrose, sodium ferric gluconate complex, lower molecular weight iron 
dextran, and higher molecular weight iron dextran, respectively, whereas absolute rates of death were 
0.11, 0.25, 0.75, and 0.78 per 106 doses, respectively. Therefore, the rates of intravenous iron-related 
ADEs reported to the FDA are extremely low and life-threatening and other ADEs appear to be lower 
with the use of non-dextran iron formulations [13].  
B. Infection and iron. Current information on the relationship between IV iron and infection, and 
between IV iron and oxidative stress deserves special consideration. Elemental iron is an essential 
growth factor for bacteria with many species expressing iron transport proteins that compete with 
transferrin, and patients with iron overload seem to be at increased risk of infection [14]. In contrast, in 
the peritoneal dialysis population, patients receiving IV iron had no increased risk of peritonitis 
compared with those who did not [15]. In addition, a study of 988 dialysis patients found increased risk 
of bacteraemia (RR 0.7 for each 1g/dL less of Hb) in the presence of anaemia [16]. Nevertheless, 
despite the lack of definitive clinical data, it seems sensible to avoid giving intravenous iron in acute 
infection. 
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C. Oxidant damage and iron. Biologically active iron, which all IV iron agents release, also plays a 
role in inflammation, oxidant stress and the propensity for accelerated atherosclerosis. Persistent 
oxidative stress in CKD patients promotes inflammation and, in turn, atherogenesis and increased 
cardiovascular morbidity and mortality. However,  
available evidence relating IV iron administration to atherogenesis is indirect, and there is little 
evidence that IV iron adversely affects survival in patients with dyalisis-dependent CKD. Nevertheless, 
the evidence argues for caution, not complacency, in prescribing IV iron (7). 
D. Iron overload. If iron status is not followed closely, patients receiving IV iron may develop iron 
overload. In short, markers of risk, stores, and efficacy all prompt a single conclusion: IV iron is 
associated with evidence of increased risk and excessive tissue iron stores in patients with a serum 
ferritin >600 ng/mL and a lack of therapeutic efficacy in the patient with a serum ferritin >500 ng/mL. 
The evidence supports withholding IV iron in patients with pre-treatment ferritin values >500 ng/mL [7]. 
However, in CKD patients, administered iron accumulates preferentially in the macrophages of the 
RES, including the Kupffer cells of the liver. Therefore, the deleterious effects of the overload are of 
lesser significance compared with idiopathic haemochromatosis, where iron accumulation occurs 
primarily in parenchymal cells [12]. 
3. INTRAVENOUS IRON THERAPY IN NON-SURGICAL PATIENTS 
3.1 Pregnancy and post-partum 
Anaemia due to iron deficiency or iron loss is common during and after pregnancy [17]. Bayoumeu et 
al [18], in a random, prospective, open study, compared intravenous iron sucrose with oral iron sulfate 
in 50 patients with haemoglobin between 8 and 10 g/dL and ferritin <50 ng/mL. On day 30, no 
differences in Hb increase were observed between groups, though ferritin levels were higher in the IV 
group both on day 30 and at delivery. In contrast, Al et al (19) in a randomized open-label study in 90 
patients with similar Hb (8 -10.5 g/dL) but lower ferritin value (<13 ng/mL) found that iron sucrose 
increased Hb and restored iron stores faster than oral iron during the first month of treatment. Similar 
results occurred in a non-randomized prospective study where 111 pregnant women with IDA (ferritin 
<20 ng/mL) were sequentially assigned to IV or oral iron [20]. Overall, between 1992 and 2005, more 
than 500 pregnant women with IDA were treated at the Zurich Obstetrics Clinic (mean iron sucrose 
total dose,1000 mg) without serious adverse events. The mean increase in Hb was 2 g/dL [17]. From 
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the results of these studies, iron sucrose appears to be a treatment without serious side effects for the 
correction of pregnancy anaemia and iron stores depletion.  
In postpartum anaemia, Breymann et al [21] randomised 40 patients (Hb = 86 ± 11 g/L) to receive iron 
sucrose, or oral iron alone, daily for 4 days beginning 48-72 h postpartum, and found that both 
regimens were of equal efficacy in both rate and degree of Hb recovery in the postpartum period. In 
contrast, two more recent studies found IV iron sucrose to be better than oral iron for treating anaemic 
postpartum mothers [22,23]. But Bhandal et al [22] gave iron only to those patients with proven ID 
anaemia, whereas Breyman et al [21] excluded those with antepartum anaemia. Thus, oral and IV iron 
appear to be equivalent except perhaps in particular circumstances. Additional treatment with rHuEPO 
should be reserved for those patients with profound postpartum inflammation (e.g., anaemic patients 
after Caesarean section) [24].  
3.2 Inflammatory bowel disease 
About a third of patients with inflammatory bowel disease (IBD) suffer from recurrent anaemia, which 
significantly affects their quality of life. In IBD, blood loss in the intestine overwhelms duodenal iron 
absorption, resulting in negative iron balance and ID, and combines with anaemia of chronic 
inflammatory disease. These contribute most to the development of IBD anaemia. Cobalamin or folate 
deficiency and various other causes of anaemia, such as haemolysis, occur less often [25].  
In these patients, IBD-specific factors may hinder the efficacy of oral iron therapy. Among them are 
gastrointestinal side effects of oral ferrous iron (release of activated hydroxyl radicals) or iron 
absorption reduced by inflammation [26].These limitations of oral iron therapy in IBD mean that we 
must consider parenteral routes. In a study of IBD patients with poor response or intolerance to oral 
iron, the administration of iron sucrose (200 mg once or twice weekly to replenish total iron deficiency) 
resulted in a positive response (Hb increment 2 g/dL or correction of anaemia) in 60% of patients 
within 8 weeks and in 90% within 12 weeks [27]. However, a randomized, controlled, open-label, 
multicenter trial in 46 patients with anemia and transferrin saturation 20% and/or serum ferritin 
concentrations 20 ng/mL, found no differences in Hb increment within 6 weeks between patients 
receiving iron sucrose or iron sulfate. But they did build up iron stores (ferritin in the range of 200 
ng/mL after six weeks) [28]. In addition, five patients (20.8%) receiving iron sulfate had to discontinue 
the study drug because of intractable gastrointestinal reactions, whereas only one patient (4.5%) on 
iron sucrose had to withdraw because of side effects [28]. In another randomized study, oral ferrous 
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fumarate, but not intravenous iron sucrose, increased clinical disease activity in IBD patients, whereas 
intravenous iron sucrose increased intravascular oxidative stress [29]. Thus, despite equal short-term 
efficacy and tolerability, iron sucrose seems better tolerated by the gastrointestinal tract. But we need 
further research on when best to start treatment, target Hb and ferritin levels, and the effects of 
intravenous iron on the clinical course of IBD. 
3.3 Congestive heart failure 
Anaemia correlates with chronic heart failure (CHF), not only because it is common but also because 
it indicates greater impairment in functional capacity, and independently predicts mortality and 
hospitalization in CHF patients [30]. The causes of anaemia in CHF patients are probably many. A 
vicious cycle may exist between heart failure, anaemia and CKD, the "cardio-renal-anaemia" 
syndrome [30]. In anaemic CHF patients, correction of anaemia with rHuEPO and oral iron (increase 
in Hb from 10.4 ± 0.6 to 12.4 ± 0.8 g/dL; p<0.01) leads to improvement in New York Heart Association 
status, exercise endurance, oxygen use during exercise, renal function, and plasma B-type natriuretic 
peptide levels. It also reduces the need for hospitalization [31]. Both ID and FID may also play a role in 
the cardio-renal-anaemia syndrome. Bolger et al. [32] found that iron sucrose increases Hb levels 
(11.2 ± 0.7 vs. 12.6 ± 1.2; p<0.001), reduces symptoms, and improves exercise capacity in anaemic 
patients with CHF. In addition, they found no adverse events relating to drug administration or during 
follow-up. Other randomized trials, such the IRON-HF [33], could indicate the best Hb level at which to 
start treatment, the target Hb, which patients might benefit from IV iron alone, or when IV iron should 
be supplemented with rHuEPO. 
3.4 Chronic kidney disease 
Nowadays, the administration of ESAs with iron supplements, but not ABT, is standard therapy for the 
anaemia of CKD, although some patients still receive transfusions. On the other hand, IV iron alone 
partially corrects this anaemia. In anaemic non-dialyzed CKD patients, the haematocrit response is 
more rapid in patients receiving IV iron with low-dose rHuEPO, but 50% of patients with iron alone had 
greater than 3% increase in haematocrit. In addition, 29% of these patients reached the target 
haematocrit (35%) compared with 40% of those receiving the combination therapy [34]. Administration 
of IV iron to CKD patients significantly increases the haematocrit, with 35-40% of them reaching target 
haematocrit without rHuEPO [35,36]. So IV iron alone can correct anaemia in CKD, possibly enough 
to avoid ABT, but many patients will also need ESA supplementation to attain the target Hb level. 
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3.5 Anaemia of cancer 
Patients with cancer may have anaemia with ID or FID as a result of their disease or its treatment. 
Supportive care with ESAs in these conditions can lead to an insufficient supply of iron for 
incorporation into erythrocytes. In cancer patients receiving chemotherapy, IV iron dextran or ferric 
gluconate increases the haematopoietic response to rHuEPO compared with patients receiving oral 
iron or no iron (70%, 40%, and 35%, respectively) [37,38]. The effects on Hb levels (2.4, 1.5 and 1.2 
g/dL, respectively) and measures of iron metabolism were notably greater with IV iron formulations 
than with oral. However, the FDA recently issued an alert giving new safety information for 
erythropoiesis-stimulating agents (ESAs: darbepoetin alfa, epoetin alfa). Analysis of four new studies 
in patients with cancer found more serious and life-threatening side effects and even death with ESAs. 
Use of these agents to achieve a target hemoglobin of 12 g/dL or greater in cancer patients: 1) 
shortened the time to tumor progression in patients with advanced head and neck cancer receiving 
radiation therapy; 2) shortened overall survival and increased mortality from disease progression in 
patients with metastatic breast cancer receiving chemotherapy; 3) increased the risk of death in 
patients with active malignant disease not under treatment with chemotherapy or radiation. These 
research studies were evaluating an unapproved dosing regimen, a patient population for which ESAs 
are not approved, or a new unapproved ESA [39]. Thus, the role of ESAs is increasingly uncertain in 
the treatment of the anaemia of cancer. 
4. INTRAVENOUS IRON THERAPY IN SURGICAL PATIENTS 
Perioperative anaemia is linked to increased postoperative morbidity and mortality, and decreased 
quality of life [40]. Preoperative anaemia, which is one of the major predictive factors for ABT in 
surgeries with moderate to high blood loss [6], may be present in one-third to one-half of them due to 
ID, chronic inflammation, or both [3,5]. Deficiency of folic acid and/or vitamin B12 is also frequent, 
especially in the older population [3,5]. Although oral iron supplementation should be preferred, it is 
time-consuming and, for some surgical patients with severe preoperative anaemia, IV administration 
might be considered.  
In contrast, postoperative anaemia occurs in up to 90% of patients [40]. Operative blood loss is the 
main cause, and may be aggravated by inadequate erythropoiesis due to inflammation, especially with 
decreased iron availability [41]. These alterations in iron metabolism also apply to critically ill and to 
trauma patients [42]. In normal persons with significant blood-loss anaemia, intravenous iron can allow 
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up to a five-fold erythropoietic response [3]. However, patients with perioperative inflammatory 
anaemia probably benefit most from the combination of rHuEPO and intravenous iron, as rHuEPO 
increases iron mobilization from the RES into RBC precursors [3]. 
4.1 Non-elective Orthopaedic Surgery. 
Three non-randomized studies evaluated iron sucrose for the treatment of acute anaemia in 
pertrochanteric (PHF) and subcapital (SHF) hip fracture patients, and found no adverse reactions to 
iron administration in any of them [43-45]. In the first two, there was a trend towards a lower 
transfusion rate (-13%), lower 30-day mortality (-11%) and shorter hospital stay (-2 days) in 75 
patients (55 PHF, 20 SHF) receiving 200-300 mg iron sucrose preoperatively (significant for SHF 
patients) when compared with a historical control group (159 patients: 102 PHF, 57 SHF) [43,44]. In a 
subsequent study, perioperative administration of 600 mg iron sucrose (plus 40,000 IU rHuEPO 
subcutaneously if Hb <13 g/dL upon admission) (n=83), together with a restrictive transfusion protocol 
(transfusion trigger: Hb <8 g/dL and/or symptoms of acute anaemia), also resulted in a reduction of the 
percentage of transfused patients (24% vs. 71%, respectively; p<0.05) when compared with a parallel 
control group from another surgical unit in the same institution (n=41) [45]. In addition, there was a 
trend towards reduced 30-day mortality (7% vs. 15%, respectively) [45]. 
4.2 Elective Orthopaedic Surgery 
In a recent study, 27 consecutive patients scheduled to undergo major orthopaedic surgery were given 
preoperative IV iron infusions (600-1200 mg over 2-3 weeks) because of intolerance to oral iron 
administration, poor intestinal absorption, chronic inflammatory anaemia, or functional iron deficit [46]. 
Twenty patients received preoperative IV iron plus rHuEPO and 7 received only IV iron (rHuEPO 
therapy being ruled out because of cardiovascular or thromboembolic disease, or because they had 
pure iron deficiency). There were no differences in preoperative Hb increase (+1.7 g/dL) or 
postoperative transfusion rate between groups [46]. Although no comparison was made with oral iron, 
these data suggest that IV iron therapy may improve the preoperative haemoglobin in this patient 
population, whereas rHuEPO should be reserved for those not responding to IV iron.  
A more recent study gave immediate perioperative iron sucrose (2 x 200 mg, days 0 and +2) plus one 
dose of rHuEPO (40,000 IU subcutaneously on day 0, only for patients with preoperative Hb < 13 
g/dL) to 311 patients undergoing surgery for total knee replacement (TKR) under a restrictive 
transfusion protocol. Again, they found no adverse effects of iron sucrose or rHuEPO administration, 
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and only 4% of the patients received ABT [47]. Interestingly, the ABT rate in patients with preoperative 
Hb < 13 g/dL (9%) was no different from that reported with the administration of 4 x 40,000 IU rHuEPO 
(10.8%) [48]. In addition, FDA warned that the preliminary results of a 681 patient, multi-center, 
randomized, open-label study of rHuEPO (4 x 40,000 IU) compared with standard-of- care orthopaedic 
surgery showed that the frequency of deep venous thrombosis in patients treated with rHuEPO was 
more than twice that of patients who received only blood conservation care (4.7% vs. 2.1%, 
respectively) [39]. 
For postoperative anaemia, the administration of oral iron after orthopaedic surgery does not appear 
to be worthwhile [49-51]. However, iron sucrose (3 mg/kg/day) is more effective in restoring 
postoperative Hb after spinal surgery in children than historical controls receiving oral iron [52], and 
postoperative iron sucrose reduced the requirements for ABT in hip arthroplasty [53]. On the other 
hand, Karkouti et al [54] conducted a double-blinded, placebo-controlled randomized study of 31 adult 
patients without preoperative anemia (13 cardiac surgery, 18 orthopaedic) whose Hb was 7 to 9 g/dL 
on the first postoperative day (POD 1). Patients were assigned to one of three groups: control, IV iron 
alone (200 mg of iron sucrose on POD 1, 2, and 3), or IV iron with rHuEPO (600 U/kg on POD 1 and 
3). There were no differences in Hb at one or six weeks after surgery, although reticulocyte counts 
were higher on POD-7 in the combination group. The authors concluded that early postoperative 
treatment with IV iron alone or in combination with rHuEPO does not appear to accelerate early 
recovery from postoperative anemia. However, this study has several limitations, including the small 
number of patients recruited relative to the number of patients screened (which limits generalizing the 
results), the inclusion of cardiac and orthopedic surgical patients (whose postoperative inflammatory 
reactions differ in intensity and duration), and the lack of parameters of baseline iron status. In 
addition, the authors recognized that this study cannot exclude the possibility that higher doses or 
different timing of postoperative IV iron and rHuEPO might accelerate the correction of postoperative 
anaemia [54]. 
In this regard, one report found that 71% of Hb loss and 92% of preoperative Hb was recovered by 
postoperative day 30 in TKR patients receiving perioperative intravenous iron (2 x 200 mg, days 0 and 
+2) with (n=19) or without EPO (n=129), and only 15% of them remained anaemic [55]. This Hb 
reconstitution was attained without a reduction of iron stores. On the other hand, a similar Hb 
reconstitution (80%) was found using oral iron or no treatment, but this was at postoperative day 56 
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and associated with significant reduction of ferritin levels in patients that were not transfused [56]. 
Hence, perioperative IV iron may hasten the recovery from postoperative anaemia and preserve iron 
stores in TKR patients, especially those with preoperative ferritin <100 ng/mL [55]. We offer a tentative 
algorithm of perioperative iron administration in patients undergoing major orthopaedic surgery (figure 
2). 
4.3 Cardiac surgery 
In the postoperative period after uncomplicated coronary artery bypass surgery, oral iron neither 
restored red blood cell mass nor maintained total body iron stores [57]. In contrast, postoperative 
intravenous iron preserved iron stores during recovery from anaemia [59]. Moreover, the increase in 
Hb level from postoperative day 4 (nadir) to postoperative day 30 was 1 g/dL higher in patients who 
received intravenous iron supplements, with or without rHuEPO, compared with those who received 
placebo [58]. However, as mentioned above, the study by Karkouti et al. did not find any benefit of 
postoperative IV iron and rHuEPO in cardiac surgery [54]. Finally, a retrospective study of 863 cardiac 
surgery patients showed no differences in infection rates between patients receiving intravenous iron 
plus rHuEPO (n=302) or ABT (n=561), as indicated, for the correction of postoperative anaemia [59]. 
Adult cardiac surgery patients who received EPO had fewer ABT exposures (60/195, 31% vs. 56/104, 
54%)(RR, 0.57; 95% CI, 0.43-0.75; P < 0.001), but the total rHuEPO dose varied greatly. Evidence is 
lacking that IV iron is better than oral iron in supporting rHuEPO treatment in cardiac surgery [60]. 
4.4 Colorectal cancer 
Iron deficiency and anaemia are frequent in colorectal cancer (CRC) patients. Significant risk factors 
for anaemia include patient’s age, tumour site (right colon), and tumour size (large), but not clinical 
stage or histological type. Thus, both IDA and ID might be therapeutic targets in CRC patients. 
Oral iron supplementation (sodium ferrous citrate, 200 mg/day) to CRC patients resulted in higher Hb 
levels immediately before surgery, and fewer patients receiving intraoperative ABT (9.4% vs. 27.4%, 
P<0.05), when compared with a control group [61]. But there were no significant differences in 
postoperative Hb levels or transfusion volumes between the two groups [61]. In another study, 43 
colorectal cancer patients received preoperative oral iron if Hb > 14 g/dL and iron deficiency; iron 
sucrose (200 mg/week) if Hb 10-14 g/dL; or iron sucrose (200 mg twice a week) if Hb < 10 g/dL, for 2-
3 weeks. Seventeen of these patients also received postoperative iron sucrose (200 mg on days 0, 2, 
and 4). A retrospective series of patients not receiving iron was used as a control group (n = 66). 
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Despite a lower baseline Hb (12.3 vs. 11.5 g/dL; P < 0.05), iron therapy reduced the transfusion index 
(4.0 vs. 1.3 unit/patient; P < 0.05) and the percentage of patients who received preoperative ABT 
(33% vs. 9%; P<0.05), but not the percentage of patients administered perioperative ABT (48% vs. 
35%; P=0.161). However, the treatment was ineffective in patients with a high transfusion index (> 5 
units/patient) [62]. 
The effectiveness of perioperative intravenous iron can be enhanced by concomitant rHuEPO 
administration. Thus, perioperative treatment with rHuEPO alone reduced the risk of exposure to ABT 
in patients with moderate anaemia scheduled for CRC surgery (38% vs. 47%; RR, 0.81; 95% CI, 0.61-
1.00; P = 0.054), whereas a reduction of both the percentage of transfused patients and the number of 
transfused units was observed only in those receiving both rHuEPO and intravenous iron. Additionally, 
the use of intravenous iron allowed for a significant reduction in the total dose of rHuEPO [62]. 
Nevertheless, even when this is a short term therapy, we should take into account the above-
mentioned uncertain role of rHuEPO on cancer patients’ outcome. 
4.5 Gynaecological surgery 
In gynaecological practice, most blood transfusions occur at the time of radical surgery. Many patients 
already have IDA or ID, from chronic blood loss, so preoperative correction of anaemia emerges as a 
possible alternative to ABT. In two randomized controlled studies of 81 healthy, mildly anaemic 
women who underwent total hysterectomy, patients who received rHuEPO once weekly for 3-4 weeks 
with oral iron had higher preoperative Hb levels and less need of ABT than those who received only 
oral iron [63,64]. But in one of these studies, the authors found that in most cases of myoma iron alone 
seemed as efficacious as iron plus rHuEPO in correcting anaemia preoperatively [63]. Another study 
evaluated the efficacy and safety of treatment with intravenous iron for postoperative anaemia in 52 
gynaecological surgery patients (46% abdominal hysterectomy; 21% myomectomy) with Hb levels 
less than 10 g/dL, who received three 200 mg doses of IV iron sucrose on consecutive days. Fifteen 
days after the last dose, Hb was increased by 2.7 g/dL (95% CI 2.2-3.1; p<0.001), only one patient 
had side effects (pain at the injection site), and no patient received ABT [65]. Therefore, the low 
incidence of serious side effects and the rapid recovery of Hb levels make iron sucrose a safe, 
effective drug for treating perioperative anaemia in this patient population.  
5. CRITICALLY ILL PATIENTS 
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More than a third of ICU patients have FID, a condition that cannot be corrected with oral iron 
supplements [42,66]. Patients with FID have longer episodes of systemic inflammatory response 
syndrome (SIRS) and longer ICU stays than those without FID [66]. In contrast, critically ill patients 
with anaemia treated with IV iron sucrose (20 mg/day) experienced an improvement of SIRS 
(reduction of C-reactive protein levels) and a trend to reduced transfusion and mortality rates, 
compared with those in a control group who only received folic acid [67]. In a recent study, the number 
of RBC units transfused and the percentage of transfused patients were lower in ICU patients 
receiving IV iron sucrose (100 mg three times a week) and subcutaneous rHuEPO (40,000 units once 
a week or three times a week) than in patients receiving iron sucrose alone, although there were no 
differences in morbidity or mortality rates among the three groups [68] (Table 4). This protocol resulted 
in both a lower transfusion rate and a net increase in Hb levels, when compared with data reported by 
Corwin et al. [69] (Table 4). Thus, the administration of intravenous iron to critically ill patients seems 
to be safe and effective in improving the dose-dependent response to rHuEPO. But it is not yet clear 
whether the administration of rHuEPO to ICU patients gives a better outcome. This indicates that 
patient selection is important, and better rHuEPO and intravenous iron titrations are needed to 
improve morbidity, mortality and cost-effectiveness. 
6. CONCLUSIONS. 
Anaemia is common in patients admitted to hospital medico-surgical departments, and in the critically 
ill. It is most often due to absolute ID or FID (Table 1). In contrast, postoperative anaemia is mainly 
caused by perioperative blood loss, and might be aggravated by inflammation-induced depression of 
erythropoiesis. All these mechanisms may affect the anaemia of the critically ill. 
We should take note of patients who might receive perioperative transfusions on the basis RBC mass, 
transfusion trigger, and expected blood loss (e.g., using Mercuriali’s algorithm) [70]. Therefore, 
whenever clinically feasible, patients undergoing elective surgery with a high risk of postoperative 
anaemia should have tests for Hb [71] and iron status (serum iron, ferritin, and transferrin saturation 
index) at least 30 days before the scheduled surgical procedure. For patients older than 60 years, 
vitamin B12 and folic acid should also be measured [72]. Unexplained anaemia should always be 
considered secondary to some other process and, therefore, elective surgery should be deferred 
pending diagnosis [71]. 
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Administration of IV iron, with or without EPO, to medical and surgical patients seems to be safe, as 
very few severe side-effects have been observed. It may result in lower transfusion requirements, 
shorter length of hospital stay, and hastened recovery from anaemia. However, many of the 
recommendations given for IV iron are not supported by much evidence (Table 5) and this must be 
borne in mind when making decisions for a particular patient. Because of this, we need more large, 
randomized controlled trials on the safety, efficacy and cost-effectiveness of IV iron for treating 
anaemia in the clinical settings reviewed. 
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Table 1. Main causes of iron deficiency 
 
A. Increased Demands  
• Growth during infancy and childhood  
• Treatment with erythropoiesis-stimulating agents 
B. Increased Losses  
•  Phlebotomy  
Blood donation  
Dialysis (particularly haemodialysis) 
•  Haemorrhage  
Surgery  
Trauma  
Gastrointestinal bleeding  
Genitourinary bleeding  
Respiratory tract bleeding 
C. Insufficient Intake  
•  Malnutrition  
•  Inappropriate diet with deficit in bioavailable iron and/or ascorbic acid  
•  Malabsorption  
Gastric resection  
Helycobacter pylori infection  
Malabsorption syndromes (Crohn's disease and celiac disease) 
• Drug interference (gastric antiacid agents and antisecretory drugs) 
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Table 2. Main laboratory tests for the diagnosis of iron deficiency. 
 
A. Measurements providing evidence of iron depletion in the body 
• Serum iron 
• Transferrin 
• Total iron binding capacity (TIBC) 
• Transferrin saturation 
• Ferritin (Ft) 
• Soluble transferrin receptors (sTfR)   
• Ratio of sTfR to serum Ft (sTfR/log Ft) 
B. Measurements reflecting iron deficient red cell production 
• Hb 
• Mean corpuscular volume (MCV) 
• Variability in red cell size (RDW) 
• Mean corpuscular Hb (MCH) 
• Percentage of hypochromic red cells 
• Reticulocyte Hb content 
 
 25
Table 3. Some chemical and pharmacokinetics characteristics of the different intravenous iron 
formulations. 
 
 
Iron dextran 
(HMW) 
Iron dextran 
(LMW) 
Iron 
gluconate 
Iron 
sucrose 
Molecular weight (kD) 265 73 38 43 
Particle diameter (nm) 30 ± 10 ---- 3 ± 1 7 ± 4 
Initial distribution volume (L) 3.5 3.5 6 3.4 
Plasma half-life (h) 60 30 1 6 
Direct iron donation to transferrin 
(% injected dose) 
1-2 1-2 5-6 4-5 
Labile iron release - - +++ ±  (1) 
Maximal single dose (mg) Total dose Total dose 125 300 
 
HMW, high molecular weight; LMW, low molecular weight; ADE, adverse drug events 
(1) If the infusion speed >4 mg Fe3+/min or dose >7 mg Fe3+/kg 
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Table 4. Effectiveness of rHuEPO and intravenous iron in critically ill patients 
 
 Corwin, 2002 1 Georgopoulos, 2005 2 
 Control rHuEPO Control rHuEPO-1 rHuEPO-2 
Patients (n) 652 650 48 51 49 
Transfusion (%) 60.8 50.5* 59.3 37.3* 26.5* 
Transfused units 1963 1590* 138 33* 23* 
Transfusion index (U per patient) 3.0 ± 5.4 2.4 ± 4.8  2.8 ± 3.9 0.6 ± 1.0* 0.5 ± 0.9 
Baseline Hb (g/dL) 10 ± 1.2 10 ± 1.2 9.2 ± 1.3 9.3 ± 1.2 9.2 ± 0.9 
Observed  ΔHb (g/dL) 0.9 ± 0.9 1.3 ± 2.0* 0.7 ± 1.5 1.4 ± 1.7* 2.2 ± 2.2* 
Net ΔHb (g/dL)3 – 2.1  – 1.1 – 2.1 + 0.8 + 1.7 
Mortality 18.4 17.1 14.6 9.8 20.4 
 
1 rHuEPO 40,000 IU once a week, oral iron (IV iron if intolerance to oral iron or development of iron 
deficiency), transfusion threshold Hb <9 g/dL. 
2 rHuEPO 40,000 IU once a week (rHuEPO-1) or three times a week (rHuEPO-2), intravenous iron 
sucrose 100 mg three times a week, transfusion threshold Hb <7 g/dL. 
3 Net ΔHb (g/dL) = Observed ΔHb (g/dL) - Transfusion index (U per patient); assuming that 1 packed 
red cell unit increases Hb concentration by 1 g/dL. 
* P<0.05 
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 Table 5. Grade of recommendation of intravenous iron therapy for treating anaemia and/or avoid 
allogeneic transfusion medico-surgical patients, according to modified Delphi methodology (75). 
 
Clinical Setting Recommendation 
A. Medical patients  
• Pregnancy and post-partum C 
• Inflammatory bowel disease C 
• Congestive heart failure D 
• Rheumatoid arthritis D 
• Chronic kidney disease B 
• Anaemia of cancer C 
B. Surgical patients  
• Non-elective orthopaedic surgery D 
• Elective orthopaedic surgery D 
• Cardiac surgery E 
• Colo-rectal cancer surgery E 
• Gynaecological surgery D 
C. Critically ill patients D 
 
Grades of recommendation: A, supported by at least 2 studies of level 1 (RTCs with large sample 
populations, clear objectives and low or a very low risk of bias, or well-conducted meta-analyses or 
systematic reviews); B, supported by 1 study of level I; C, supported by studies of level II (RTCs with 
small sample populations, clear objectives and moderate risk of bias); D, supported by studies of level 
III (Observational studies with contemporary controls); E, supported by studies of level IV 
(Observational studies with historical controls) or V (Non-analytic studies, e.g. case reports, case 
series. Expert opinion) 
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Figure 1.  Main pathways of iron absorption, distribution and storage in humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keys. 1. Ferrireductase; 2. Divalent metal transporter (DMT-1); 3. Haem receptor; 4. Haem 
hydroxilase; 5. Ferroportin (Fpn1); 6. Haefastin; 7. Transferrin receptor-1 (TfR1); 8. Natural resistance 
macrophage protein (Nramp-2); 9. Transferrin receptor-2 (TfR2); 10. Ceruloplasmin; 11. Others: 
bacteria, lactoferrin, Hb-haptoglobin, Haem-haemopexin, etc. 12. Others: Hb, haem, ferritin.     
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Figure 2. A tentative algorithm for the use of intravenous iron sucrose in a 70 kg patient scheduled for 
major orthopaedic surgery with an expected haemoglobin drop of 4 g/dL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total iron dose (mg) = Total iron deficiency (TID) + Surgical iron loss (SIL) 
TID = [Target Hb (g/dL) – Actual Hb (g/dL)] x Weight (kg) x 2.4; where target Hb is 14 g/dL and 2.4 is 
a factor (Hb iron content x blood volume x 1000) 
SIL = expected Hb drop (g/dL) x 165; assuming that 165 mg of iron are needed to raise Hb by 1 g/dL. 
Day, perioperative day (- preoperative, + postoperative); Ft, ferritin; CRP, C-reactive protein. 
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